» Articles » PMID: 35326590

Prediction of Short and Long Survival After Surgery for Breast Cancer Brain Metastases

Abstract

Background: Brain metastases requiring surgical treatment determine the prognosis of patients with breast cancer. We aimed to develop the scores for the prediction of short (<6 months) and long (≥3 years) survival after BCBM surgery. Methods: Female patients with BCBM surgery between 2008 and 2019 were included. The new scores were constructed upon independent predictors for short and long postoperative survival. Results: In the final cohort (n = 95), 18 (18.9%) and 22 (23.2%) patients experienced short and long postoperative survival, respectively. Breast-preserving surgery, presence of multiple brain metastases and age ≥ 65 years at breast cancer diagnosis were identified as independent predictors of short postoperative survival. In turn, positive HER2 receptor status in brain metastases, time interval ≥ 3 years between breast cancer and brain metastases diagnosis and KPS ≥ 90% independently predicted long survival. The appropriate short and long survival scores showed higher diagnostic accuracy for the prediction of short (AUC = 0.773) and long (AUC = 0.775) survival than the breast Graded Prognostic Assessment score (AUC = 0.498/0.615). A cumulative survival score (total score) showed significant association with overall survival (p = 0.001). Conclusion: We identified predictors independently impacting the prognosis after BCBM surgery. After external validation, the presented scores might become useful tools for the selection of proper candidates for BCBM surgery.

Citing Articles

Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients.

Wang Y, Xu H, Sa Q, Li L, Han Y, Wu Y BMC Cancer. 2024; 24(1):1262.

PMID: 39390441 PMC: 11465582. DOI: 10.1186/s12885-024-12983-3.

References
1.
Lentzsch S, Reichardt P, Weber F, Budach V, Dorken B . Brain metastases in breast cancer: prognostic factors and management. Eur J Cancer. 1999; 35(4):580-5. DOI: 10.1016/s0959-8049(98)00421-3. View

2.
Taillibert S, Le Rhun E . [Epidemiology of brain metastases]. Cancer Radiother. 2015; 19(1):3-9. DOI: 10.1016/j.canrad.2014.11.001. View

3.
Zafir-Lavie I, Sherbo S, Goltsman H, Badinter F, Yeini E, Ofek P . Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases. J Control Release. 2018; 291:80-89. DOI: 10.1016/j.jconrel.2018.10.017. View

4.
Shyamala K, Girish H, Murgod S . Risk of tumor cell seeding through biopsy and aspiration cytology. J Int Soc Prev Community Dent. 2014; 4(1):5-11. PMC: 4015162. DOI: 10.4103/2231-0762.129446. View

5.
Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8):1700-1712. PMC: 6246241. DOI: 10.1093/annonc/mdx308. View